Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myostatin, also known as growth differentiation factor 8 (GDF-8), is a secreted protein that acts as a key negative regulator of skeletal muscle growth and development. It is almost exclusively expressed in skeletal muscles, where it functions both before and after birth to limit muscle mass by inhibiting myoblast proliferation and differentiation. It signals through ActRIIB/A receptors, activating SMAD2/3 and inhibiting Akt signaling. Dysregulation contributes to muscle wasting, while inhibition is explored for treating muscle loss diseases.
Binds activin type II receptors (ActRIIB > ActRIIA), activates SMAD2/3 signaling, inhibits Akt signaling, and promotes ubiquitin-mediated degradation of muscle proteins, ultimately inhibiting myoblast proliferation and differentiation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myostatin (None).